Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013:2013:176418.
doi: 10.1155/2013/176418. Epub 2013 Oct 28.

Management of adenovirus in children after allogeneic hematopoietic stem cell transplantation

Winnie Wy Ip  1 , Waseem Qasim
Affiliations
Review

Management of adenovirus in children after allogeneic hematopoietic stem cell transplantation

Winnie Wy Ip et al. Adv Hematol. 2013.

Abstract

Adenovirus (ADV) can cause significant morbidity and mortality in children following haematopoietic stem cell transplantation (HSCT), with an incidence of up to 27% and notable associated morbidity and mortality. T-cell depleted grafts and severe lymphopenia are major risk factors for the development of adenovirus disease after HSCT. Current antiviral treatments are at best virostatic and may have significant side effects. Adoptive transfer of donor-derived virus-specific T cells has been shown to be an effective strategy for the prevention and treatment of ADV infection after HSCT. Here we review progress in the field and present a pathway for the management of adenovirus in the posttransplant setting.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Structure of adenovirus.
Figure 2
Figure 2
Algorithm for the management of ADV reactivation in children after allogeneic stem cell transplantation.
Figure 3
Figure 3
Protocols for generating virus-specific T cells. (a) Donor identified as ADV responder by IFN-γ secretion assay (Miltenyi Biotec, Bergisch Gladbach, Germany). Peripheral blood mononuclear cells (PBMC) isolated and incubated overnight with ADV Hexon protein. Responding cells captured with IFN-γ reagent, anti-IFN-γ microbead and magnetically enriched with CliniMACS (Miltenyi Biotec) [60]. (b) Donor PBMC incubated over 10 days with ADV5 hexon peptide and cytokines. Expanded cells isolated and infused into patients after QA/QC testing [61]. (c) EBV-transformed B cell lines (EBV-LCLs) generated from donor PBMCs by infecting with EBV virus. Donor PBMCs are transfected with Ad5f35pp65 vector (replication-competent adenovirus-negative) and later restimulated several times by EBV-LCLs that have been transduced with the same vector [62].
See this image and copyright information in PMC

References

    1. Rowe WP, Huebner RJ, Gilmore LK, et al. Isolation of a cytopathogenic agent from human adenoids undergoing spontaneous degeneration in tissue culture. Proceedings of the Society for Experimental Biology and Medicine. 1953;84(3):570–573. - PubMed
    1. Walls T, Shankar AG, Shingadia D. Adenovirus: an increasingly important pathogen in paediatric bone marrow transplant patients. The Lancet Infectious Diseases. 2003;3(2):79–86. - PubMed
    1. Heim A. Advances in the management of disseminated adenovirus disease in stem cell transplant recipients: impact of adenovirus load (DNAemia) testing. Expert Review of Anti-Infective Therapy. 2011;9(11):943–945. - PubMed
    1. Lion T, Baumgartinger R, Watzinger F, et al. Molecular monitoring of adenovirus in peripheral blood after allogeneic bone marrow transplantation permits early diagnosis of disseminated disease. Blood. 2003;102(3):1114–1120. - PubMed
    1. Kojaoghlanian T, Flomenberg P, Horwitz MS. The impact of adenovirus infection on the immunocompromised host. Reviews in Medical Virology. 2003;13(3):155–171. - PubMed

LinkOut - more resources